ATE293689T1 - Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung - Google Patents

Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung

Info

Publication number
ATE293689T1
ATE293689T1 AT96900656T AT96900656T ATE293689T1 AT E293689 T1 ATE293689 T1 AT E293689T1 AT 96900656 T AT96900656 T AT 96900656T AT 96900656 T AT96900656 T AT 96900656T AT E293689 T1 ATE293689 T1 AT E293689T1
Authority
AT
Austria
Prior art keywords
rantes
mip
mcp
chemokine receptor
alpha
Prior art date
Application number
AT96900656T
Other languages
English (en)
Inventor
Timothy Nigel Carl Wells
Christine Anna Power
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293689(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE293689T1 publication Critical patent/ATE293689T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
AT96900656T 1995-01-27 1996-01-24 Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung ATE293689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501683.8A GB9501683D0 (en) 1995-01-27 1995-01-27 Substances and their uses
PCT/GB1996/000143 WO1996023068A1 (en) 1995-01-27 1996-01-24 A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses

Publications (1)

Publication Number Publication Date
ATE293689T1 true ATE293689T1 (de) 2005-05-15

Family

ID=10768728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96900656T ATE293689T1 (de) 1995-01-27 1996-01-24 Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung

Country Status (9)

Country Link
US (4) US6150132A (de)
EP (1) EP0805859B2 (de)
JP (2) JP3771585B2 (de)
AT (1) ATE293689T1 (de)
AU (1) AU4455896A (de)
DE (1) DE69634627T3 (de)
ES (1) ES2240989T5 (de)
GB (1) GB9501683D0 (de)
WO (1) WO1996023068A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6498015B1 (en) * 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
ATE428785T1 (de) * 1996-03-01 2009-05-15 Euroscreen Sa Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
US5939320A (en) * 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US5955303A (en) * 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
US6121023A (en) * 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
US6287805B1 (en) 1998-03-20 2001-09-11 Millennium Pharmaceuticals, Inc. Nucleic acid molecules of the protein-coupled heptahelical receptor superfamily and uses therefor
AU771946B2 (en) * 1998-08-31 2004-04-08 Oregon Health And Science University Prevention of cell migration initiation with CMV US28 receptor antagonists
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) * 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
ES2156526B1 (es) * 1999-01-20 2002-02-01 Smithkline Beecham Sa Metabolitos de streptomyces cacaoi como inhibidores de la proteina quimioatrayente de monocitos 1.
EP2275540B1 (de) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen
JP3707303B2 (ja) * 1999-06-30 2005-10-19 株式会社日立製作所 ヒスタミン計測方法およびヒスタミン計測装置
SI1270595T1 (sl) 2000-03-03 2008-12-31 Kyowa Hakko Kogyo Kk Protitelo proti CCR4 in njegov fragment
US7025968B2 (en) 2000-08-30 2006-04-11 Chemocentryx, Inc. CMV vaccines
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN1469756A (zh) 2000-10-11 2004-01-21 江头健辅 治疗肝病的药物
KR100360410B1 (ko) * 2000-11-14 2002-11-13 삼성전자 주식회사 자기 정렬된 컨택 구조를 갖는 디램 소자와 듀얼 게이트구조의 로직 소자가 복합된 ｍｄｌ 반도체 소자의 제조 방법
US20020111290A1 (en) * 2000-12-01 2002-08-15 Bernhard Homey Uses of mammalian genes and related reagents
CA2437201C (en) 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20020165161A1 (en) * 2001-05-04 2002-11-07 Surromed, Inc. Chemokine-binding proteins for treating congestive heart failure
US6821998B2 (en) * 2001-08-30 2004-11-23 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to US28
CN100430420C (zh) 2001-08-31 2008-11-05 协和发酵工业株式会社 人cdr-移植抗体及其抗体片段
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2004020584A2 (en) 2002-08-27 2004-03-11 Bristol-Myers Squibb Company Antagonists of chemokine receptors
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
WO1994007521A1 (en) * 1992-09-28 1994-04-14 Board Of Regents, The University Of Texas System Methods and compositions for treatment of allergic disease
JP3664176B2 (ja) * 1992-11-10 2005-06-22 ジェネンテック・インコーポレーテッド Ｃ−ｃ ｃｋｒ−１，ｃ−ｃケモカインレセプター
US5474983A (en) * 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
JP3532570B2 (ja) * 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses

Also Published As

Publication number Publication date
EP0805859B1 (de) 2005-04-20
US20020160015A1 (en) 2002-10-31
ES2240989T5 (es) 2008-12-16
JP2003038191A (ja) 2003-02-12
US20020187930A1 (en) 2002-12-12
US6919432B2 (en) 2005-07-19
DE69634627T3 (de) 2008-12-11
DE69634627T2 (de) 2006-03-02
EP0805859B2 (de) 2008-06-25
ES2240989T3 (es) 2005-10-16
JP3771585B2 (ja) 2006-04-26
US20050014695A1 (en) 2005-01-20
WO1996023068A1 (en) 1996-08-01
JPH10513046A (ja) 1998-12-15
US7655425B2 (en) 2010-02-02
DE69634627D1 (de) 2005-05-25
US7183063B2 (en) 2007-02-27
AU4455896A (en) 1996-08-14
US6150132A (en) 2000-11-21
GB9501683D0 (en) 1995-03-15
EP0805859A1 (de) 1997-11-12

Similar Documents

Publication Publication Date Title
DE69634627D1 (de) Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung
Ling et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation
Royer et al. Inhibition of IgE‐induced activation of human mast cells by IL‐10
AU2003288675A8 (en) Antibodies against PD-1 and uses therefor
DE69813237D1 (de) Zusammensetzungen zur behandlung von durch ccr5 mediatierten erkrankungen
Tsai et al. Origin of osteoclasts: osteoclast precursor cells
Sebastiani et al. CCL22‐induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first β‐strand of chemokine
Herbst et al. Antibodies and IL-3 support helminth-induced basophil expansion
Gómez et al. Thorns as induced mechanical defense in a long‐lived shrub (Hormathophylla spinosa, Cruciferae)
Mullazehi et al. Surface‐bound anti–type II collagen–containing immune complexes induce production of tumor necrosis factor α, interleukin‐1β, and interleukin‐8 from peripheral blood monocytes via fcγ receptor IIA: A potential pathophysiologic mechanism for humoral anti–type II collagen immunity in arthritis
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE360441T1 (de) Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
Koren‐Michowitz et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC
EP0630244A4 (de) Muscarinagonisten.
BR9307646A (pt) Pirrolopirimidinas como antagonistas de crf
TW200738660A (en) Piperidinyl derivatives as modulators of chemokine receptor activity
Onyema et al. Eosinophils promote inducible NOS–mediated lung allograft acceptance
DE60323091D1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
TNSN05158A1 (fr) Association destinee au traitement de l'adhd
Park et al. Changes of frequency and expression level of CD161 in CD8+ T cells and natural killer T cells in peripheral blood of patients with systemic lupus erythematosus
DE50009113D1 (de) Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten
Manukyan et al. Antiphospholipid antibody-mediated NK cell cytotoxicity
EP1255112A3 (de) Behandlung von T-Zellen vermittelter Krankheiten
EP1241933A4 (de) Zellen mit defizientem melanocortin-3-rezeptor, nicht-menschliche transgene tiere und verfahren zur auswahl von substanzen, die das körpergewicht regulieren können
Sabroe et al. The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down‐regulation in a ligand‐dependent manner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties